

Pregnant Women Who Use Drugs: Stigma, Science and Society

Mishka Terplan MD MPH FACOG FASAM
Professor Departments Obstetrics and Gynecology and Psychiatry
Associate Director Addiction Medicine
Virginia Commonwealth University


March Of Dimes, CA 2017



LAUDANUM.--Poison
Each Fluid Ounce Contains
45.5 GRAINS OPIUM AND 40.0 ALCOHOL
U.S.P. PREPARE







Gender and Prescription Drug Use and Misuse

| Past Year | Male | Female |
|--------------------------------------|-------|--------|
| Prescription psychotherapeutic drugs | 40.9% | 47.8% |
| "Pain Relievers" | 33.9% | 38.8% |
| Tranquilizers | 11.3% | 17.9% |
| Sedatives | 5.6% | 8.2% |
| Stimulants | 6.5% | 6.3% |

- 2.1 million Past Year Initiates Opioid Misuse
 - 0.9 million males (0.7%)
 - 1.2 million females (0.9%)
- 3300 women per day


NSDUH 2015

Opioids and Child Welfare Epidemic

Parental AOD as Reason for Removal in the United States, 1999-2014



Percent of Children with Terminated Parental Rights by Reason for Removal in the US 2014



Pregnancy and Substance Use Today



State Policies on Substance Use during Pregnancy

| Policy | Number of States |
|----------------------------------------------|------------------|
| Substance Use Considered Child Abuse | 23+DC |
| Substance Use Grounds for Civil Commitment | 3 |
| Mandatory Reporting | 23+DC |
| Targeted Programs for Pregnant Women | 19 |
| Pregnant Women Given Priority Access | 16+DC |
| Pregnant Women Protected from Discrimination | 9 |

Gutmacher Institute Feb 1 2017

Punishing Pregnant Women: Not Best Practice

Maternal-Fetal Unit

A structurally and functionally interconnected metabolic unit shared by a mother and fetus through the placenta



COMMITTEE OPINION

Number 507 • July 2015
Address Committee Opinion Number 507, November 2015

Committee on Health Care Disparities
The American College of Obstetricians and Gynecologists is committed to providing high-quality, equitable care to all women, regardless of race, ethnicity, or socioeconomic status. This committee opinion addresses the disparities in maternal and fetal outcomes associated with substance use during pregnancy and the need for equitable, evidence-based care for all women.

Refusal of Medically Recommended Treatment During Pregnancy

ABSTRACT: Many of the most vulnerable women in obstetrics are those who are unable or unwilling to accept the medical advice of their obstetrician. The obstetrician's role is to provide the best possible care for the woman and her fetus, and to ensure that the woman understands the risks and benefits of her choices. This committee opinion addresses the need for equitable, evidence-based care for all women, regardless of race, ethnicity, or socioeconomic status.


Maternal-Infant Dyad

“There is no such thing as a baby ... If you set out to describe a baby, you will find you are describing a baby and someone. A baby can not exist alone, but is essentially part of a relationship”
(D.W. Winnicott 1966)




Punishing Pregnant Women: Not Best Practice

- Discriminatory in how applied
 - Although SUDs affect all, white women more likely to use in pregnancy, black women and poor women far more likely to be prosecuted.
- Not grounded in evidence
 - Harms of illicit substances exaggerated; effects of licit substances minimized
- Unintended consequences
 - Policies drive women from PNC, SUD treatment
 - PNC ameliorates adverse effects of substances in using women



-A primary, **chronic** disease of **brain reward, motivation, memory and related circuitry**. Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual manifestations. (ASAM)

- A chronic, relapsing disease characterized by compulsive drug seeking and use despite harmful consequences as well as neurochemical and molecular changes in the brain. (NIDA)



Addiction: Brain-centered disease whose visible symptoms are behaviors

-A primary, **chronic** disease of **brain reward, motivation, memory and related circuitry**. Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual manifestations. (ASAM)


- A chronic, relapsing disease characterized by compulsive drug seeking and use despite harmful consequences as well as neurochemical and molecular changes in the brain. (NIDA)

Pregnant Women Who Use Drugs


Pregnant Women Who Use Drugs



Pregnant Women Who Use Drugs



Pregnant Women Who Use Drugs




Women with SUD in pregnancy


- **Mental Health**
 - Two thirds co-occurring mental health disorders (Benningfield 2010)
 - Past 30 days: Mood disorder (50%), Anxiety (40%), PTSD (16%)
 - Childhood trauma: 50-90% physical or sexual abuse (Cormier 2000)
 - 60-80% past year intimate partner violence (Engstrom 2012, Tuten 2004)
 - Chronic pain worse in IPV survivors (Wuest 2008)
- **Reproductive Health**
 - Unplanned pregnancy: 80% (Heil 2012)
 - Low rates of contraception (Terplan 2015)
 - Higher rates of HIV


Women with SUD in Pregnancy

- **Other substance use**
 - High rates of smoking (>90%)
- **Nutritional other medical needs**
- **Social functioning**
 - Inadequate social supports
 - 67% their parents used drugs (Finnegan 1991)
 - Unpredictable parenting models
 - Children – childcare needs
- **Stigma and Shame**
- **Prior poor experiences with providers**
- **Fear of CPS**

- **Pregnant women with SUD have unique set of needs across multiple domains – domains that affect both obstetric health and outcomes and addiction treatment**
- **Care needs to address those needs**
- **“Gold Standard” – Integration**
 - Comprehensive co-located service delivery
 - Close collaboration between SUD and PNC provider







Treatment for Opioid Use Disorder in Pregnancy

- Standard of care: Medication Assisted Treatment plus behavioral counseling
 - Methadone or Buprenorphine
- Benefits
 - Stable intrauterine environment (no cyclic withdrawal)
 - Increased maternal weight gain
 - Increased newborn birth weight and gestational age
 - Increase PNC adherence
 - Decrease in (illicit) drug use - reduction of HIV/HCV acquisition and transmission
 - Decrease risk of overdose
 - Other supportive services

Principles of Treatment

- Empathy
 - Treating people with dignity and respect
- Adherence
 - People come back
 - Increase adherence by addressing needs/barriers:
 - Women/child friendly services
 - Transportation
 - Trauma informed care
 - Incentives

Pregnant Women: A Priority Population?

- “Because it is crucial that pregnant women engage in treatment for their addictions, OTPs should **give priority to admitting pregnant patients at any point during pregnancy** and providing them with all necessary care, including adequate dosing strategies as well as referrals for prenatal and follow-up postpartum services.” *Federal Guidelines for Opioid Treatment Programs, 2015*
- Pregnant women – don’t need to meet DSM criteria for use disorder to receive MAT (TIP 43)

Many pregnant women with opioid use disorder receive little or no care



- 20-80% of pregnant women with opioid use disorder are engaged in care
- Comprehensive treatment is rare and unavailable to most women
- Political climate – specifically Substance Exposed Newborn Reporting – discourages engagement in care

PREGNANT AND NON-PREGNANT WOMEN WITH SUBSTANCE USE DISORDERS: THE GAP BETWEEN TREATMENT NEED AND RECEIPT

Mishka Toplan, MD, MPH, Erica J. McNamara, MPH, Margaret S. Chisolm, MD
Journal of Addictive Diseases, 31:342-349, 2012

| Demographic Characteristics | Treatment Receipt | |
|-----------------------------|---------------------------|------------------------------|
| | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) |
| Pregnant | 1.55 (0.76, 3.08) | 0.98 (0.54, 1.81) |
| Race/Ethnicity | | |
| White | Ref | Ref |
| Hispanic | 1.27 (0.69, 2.32) | 0.87 (0.50, 1.50) |
| African American | 1.27 (0.69, 2.32) | 0.86 (0.50, 1.51) |
| Other | 0.67 (0.26, 1.73) | 0.59 (0.21, 1.61) |
| Age ¹ | | |
| 18-24 | Ref | Ref |
| 25-34 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.04) |
| 35-44 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 45-54 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 55-64 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 65-74 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 75-84 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 85-94 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 95-104 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 105-114 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 115-124 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 125-134 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 135-144 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 145-154 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 155-164 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 165-174 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 175-184 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 185-194 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 195-204 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 205-214 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 215-224 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 225-234 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 235-244 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 245-254 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 255-264 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 265-274 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 275-284 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 285-294 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 295-304 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 305-314 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 315-324 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 325-334 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 335-344 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 345-354 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 355-364 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 365-374 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 375-384 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 385-394 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 395-404 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 405-414 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 415-424 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 425-434 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 435-444 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 445-454 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 455-464 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 465-474 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 475-484 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 485-494 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 495-504 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 505-514 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 515-524 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 525-534 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 535-544 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 545-554 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 555-564 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 565-574 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 575-584 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 585-594 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 595-604 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 605-614 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 615-624 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 625-634 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 635-644 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 645-654 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 655-664 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 665-674 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 675-684 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 685-694 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 695-704 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 705-714 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 715-724 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 725-734 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 735-744 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 745-754 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 755-764 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 765-774 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 775-784 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 785-794 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 795-804 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 805-814 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 815-824 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 825-834 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 835-844 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 845-854 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 855-864 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 865-874 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 875-884 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 885-894 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 895-904 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 905-914 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 915-924 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 925-934 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 935-944 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 945-954 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 955-964 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 965-974 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 975-984 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 985-994 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 995-1004 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1005-1014 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1015-1024 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1025-1034 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1035-1044 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1045-1054 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1055-1064 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1065-1074 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1075-1084 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1085-1094 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1095-1104 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1105-1114 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1115-1124 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1125-1134 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1135-1144 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1145-1154 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1155-1164 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1165-1174 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1175-1184 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1185-1194 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1195-1204 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1205-1214 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1215-1224 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1225-1234 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1235-1244 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1245-1254 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1255-1264 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1265-1274 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1275-1284 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1285-1294 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1295-1304 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1305-1314 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1315-1324 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1325-1334 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1335-1344 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1345-1354 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1355-1364 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1365-1374 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1375-1384 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1385-1394 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1395-1404 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1405-1414 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1415-1424 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1425-1434 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1435-1444 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1445-1454 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1455-1464 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1465-1474 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1475-1484 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1485-1494 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1495-1504 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1505-1514 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1515-1524 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1525-1534 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1535-1544 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1545-1554 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1555-1564 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1565-1574 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1575-1584 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1585-1594 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1595-1604 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1605-1614 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1615-1624 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1625-1634 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1635-1644 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1645-1654 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1655-1664 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1665-1674 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1675-1684 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1685-1694 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1695-1704 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1705-1714 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1715-1724 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1725-1734 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1735-1744 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1745-1754 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1755-1764 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1765-1774 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| 1775-1784 | 0.68 (0.46, 1.02) | 0.69 (0.46, 1.03) |
| | | |

Women-Centered Drug Treatment Services and Need in the United States, 2002–2009
| Mishka Terplan, MD, MPH, Spencer Longshore, MS, and Lindsay Aspell, MD

GAO (2015): “the program gap most frequently cited was the lack of available treatment programs for pregnant women...”

- Overall provision of women-centered services in drug treatment facilities declined 2002-2009 (43%-13%, p<0.001)
- As did services specific for pregnant or postpartum women (19% in 2002 to 13% in 2009)

FIGURE 2. Percentage of substance use disorder treatment facilities offering specific women-centered services; National Survey of Substance Abuse Treatment Services (NSATS), 2002–2009, United States.

How do we narrow the treatment gap for pregnant women who use drugs?

How do we narrow the treatment gap for pregnant women who use drugs?

- 1) Assessment: Universal assessment for substance use, misuse and addiction


How do we narrow the treatment gap for pregnant women who use drugs?

- 2) Increase treatment capacity
 - Buprenorphine waived physicians
 - Under CARA (Comprehensive And Recovery Act, 2016) buprenorphine prescribing authority expanded to NPs and PAs – but not to CNMs!

How do we narrow the treatment gap for pregnant women who use drugs?

- 3) Need comprehensive lifecourse approach
 - Public Health Programming beyond the "Pregnancy Box"

Pregnant Women Who Use Drugs



Postpartum: The 4th Trimester

- Critical Period
 - Newborn care, breastfeeding, maternal/infant bonding
 - Mood changes, sleep disturbances, physiologic changes
 - Cultural norms, “the ideal mother” in conflict with what it is actually like to have a newborn
- Neglected Period
 - Care shifts away from frequent contact with PNC provider – to pediatrician
 - Care less “medical” (for mom) and shifts to other agencies (WIC)
 - Insurance and welfare realignment
 - SUD treatment provider(s) – care is constant
- Gaps in care – addressed through public health interventions – home visiting etc

Original Research
Higher Risk of Homicide Among Pregnant and Postpartum Females Aged 10–29 Years in Illinois, 2002–2011

Aligail E. Kuhl, MD, Deborah Rosenberg, MD, and Stuart E. Gilber, MD, for the Illinois Department of Public Health Maternal Mortality Review Committee Working Group





Fig. 1. Ten-year pregnancy-associated mortality rates for deaths by violence and injury compared with the leading obstetric causes in Illinois, 2002–2011. Kuhl. Pregnancy-associated Homicide in Illinois. Obstet Gynecol 2016.

Pregnancy Planning



Prevention to avoid “Crisis at Delivery”



MMWR
Morbidity and Mortality Weekly Report
March 6, 2013
Vol. 61, No. 8

Infant and Maternal Characteristics in Neonatal Abstinence Syndrome — Selected Hospitals in Florida, 2010–2011

TABLE 2. (Continued) Selected characteristics of infants with confirmed neonatal abstinence syndrome (NAS) and their mothers — selected hospitals in Florida, 2010–2011

| Maternal characteristics | No. | (%) |
|-------------------------------------------------------------------|-----|-------|
| Substances used during pregnancy^a | | |
| Opioids | 241 | 59.65 |
| Other opioids ^b | 198 | 48.18 |
| Buprenorphine | 145 | 35.95 |
| Buprenorphine | 9 | 2.22 |
| Benzodiazepines | 98 | 24.02 |
| Tobacco | 96 | 23.75 |
| Marijuana/hashish | 59 | 14.46 |
| Cocaine | 34 | 8.31 |
| Antidepressants | 17 | 4.18 |
| Other | 16 | 3.94 |
| Barbiturates | 12 | 2.95 |
| Methamphetamine | 8 | 1.97 |
| Other amphetamines/CNS stimulants | 8 | 1.97 |
| Alcohol | 5 | 1.23 |
| Other sedative hypnotics | 2 | 0.49 |
| Screening^c | | |
| Urine | 133 | 32.42 |
| Drug abuse treatment | 100 | 24.52 |
| Unknown | 32 | 7.85 |
| Urine toxicology screen performed | 20 | 4.91 |
| Yes | 210 | 51.62 |
| No/Unknown | 32 | 7.85 |
| Positive urine toxicology screen | | |
| Yes | 190 | 46.50 |
| No | 20 | 4.91 |
| Services received during birth hospitalization^d | | |
| Referral for drug addiction rehabilitation | 15 | 3.62 |
| Drug addiction counseling/Counseling on substance use and abuse | 10 | 2.45 |

Only 41% in treatment during pregnancy

Only 10% received counseling or referral from hospital

Putting it all together

- All pregnant women manifest motivation to maximize their health during pregnancy
- Most women stop or decrease use in pregnancy
- Those that can't likely have a SUD
- Engagement in care improves outcomes
- However pregnant women with SUDs have unique set of needs and experience discrimination
- Therefore care needs to be compassionate and non-judgmental, comprehensive and coordinated with PNC provider
- Preventing substance exposed pregnancies means decreasing unplanned pregnancies, increasing access to reproductive health services, specifically contraception

Thank You

- Mishka.Terplan@vcuhealth.org
